Circulating Antimicrobial Peptide LL-37 Status in Type 1 Diabetes Mellitus and its Relation with Glycemic Control

Himika Chawla, Parmita Kar, Soma Saha, Urvashi B Singh, Nikhil Tandon, Ravindra Goswami

Abstract


Antimicrobial-peptides are important molecules of constitutive innate immunity. Though patients with diabetes mellitus are generally prone to infections, there is limited information on their antimicrobialpeptide status. We assessed the circulating LL-37 antimicrobial peptide (also referred as cathelicidin) levels in patients with type 1 diabetes mellitus and its relation with their glycemic status. The LL-37 mRNA expression was assessed in the peripheral blood mononuclear cells (PBMC) by quantitative RTPCR using ß-actin and cytochrome-C1 as the reference genes in 154 subjects (Type 1 diabetes, n=111 and healthy subjects, n=43).  Serum LL-37 was quantified using sandwich-ELISA. Average HbA1c over last 2 years and current HbA1c were used to determine long-term and short-term glycemic status. LL-37 mRNA expression and serum LL-37 levels were correlated with the glycemic status. The LL-37 mRNA copies were comparable between type 1 diabetes and healthy subjects [median (IQR) = 6.7 (1.8–15.28) vs. 7.2 (2.23–21.86), respectively, P = 0.42]. There was no significant difference in serum LL-37 levels between the two groups [median (IQR) = 3.9 (2.88–7.52) vs. 5.0 (3.19–9.05) ng/ml, respectively, P = 0.52]. The LL-37 mRNA and its protein concentration showed no significant correlation with the average or current HbA1c values. The constitutive circulating antimicrobial peptide LL-37 status is not significantly altered in patients with type 1 diabetes mellitus and also not affected by their glycemic status.

Keywords


Innate-immunity, diabetes mellitus, antimicrobial peptide LL-37, cathelicidin, glycosylated hemoglobin.

Full Text:

PDF

References


Shah BR, Hux JE (2003). Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26 :510-513.

Muller LM, Gorter KJ, Hak E, et al (2005). Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41 :281-288.

Goswami R, Dadhwal V, Tejaswi S, et al (2000). Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 4 :162-166.

Casqueiro J, Casqueiro J, Alves C (2012). Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 16(S1) : S27-S36.

Geerlings SE, Hoepelman AI (1999). Immune dysfunction in patients with diabetes mellitus. FEMS Immunol Med Microbiol 26 : 259-265.

Vandamme D, Landuyt B, Luyten W, Schoofs L (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 280 : 22-35.

Torres-Juarez F, Cardenas-Vargas A, Montoya-Rosales A, et al (2015). LL-37 immunomodulatory activity during mycobacterium tuberculosis infection in macrophages. Infect Immun 83 : 44954503.

Nilsson MF, Sandstedt B, Sorensen O, Weber G, Borregaard N, Backdahl MS (1999). The human cationic antimicrobial protein (hCAP-18), a peptide antibiotic, is widely expressed in human squamous epithelia and co-localizes with interleukin-6. Infect Immun 67 : 25612566.

Dürr UH, Sudheendra US, Ramamoorthy A (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 1758 : 1408-1425.

Tangpricha V, Judd SE, Ziegler TR, et al (2014). LL-37 concentrations and the relationship to vitamin D, immune status, and inflammation in HIV-infected children and young adults. AIDS Res Hum Retroviruses 30 : 670-676.

Gonzalez-Curiel I, Castañeda-Delgado J, Lopez-Lopez N, et al (2011). Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus. Hum Immunol 72 : 656-662.

Rivas-Santiago B, Trujillo V, Montoya A, et al (2012). Expression of antimicrobial peptides in diabetic foot ulcer. J Dermatol Sci 65 : 19-26. 13. Brauner H, Lüthje P, Grünler J, et al (2014). Markers of innate immune activity in patients with type 1 and type 2 diabetes mellitus and the effect of the antioxidant coenzyme Q10 on inflammatory activity. Clin Exp Immunol 177 : 478-482.

Das M, Tomar N, Goswami R, Sreenivas V, Gupta N (2014). Effect of vitamin D supplementation on cathelicidin, IFN-γ, IL-4 and Th1/Th2 transcription factors in young healthy females. Eur J Clin Nutr 68 : 338-343.

Peleg AY, Weerarathna T, Mc-Carthy JS, Davis TM (2007). Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 23 : 3-13.

Rodacki M, Svoren B, Butty V, et al (2007). Altered natural killer cells in type 1 diabetic patients. Diabetes 56 : 177-185.

Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B (1997). Impaired leucocyte functions in diabetic patients. Diabetic Med 14 : 29-34.

Nijnik A, Hancock RE (2009). The roles of cathelicidin LL-37 in immune defenses and novel clinical applications. Curr Opin Hematol 16 : 41-47.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.